Studies showed that human epidermal growth factor receptor (HER), SHP-2, mammalian target of rapamycin (mTOR), and cyclin-dependent kinase 4/cyclin-dependent kinase 6 (CDK4/CDK6) inhibitors improved adagrasib efficacy in KRAS G12C-mutant cancers [15]. This evidence concerns the gene CDK6 and cancer.